CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtually on January 10th through the 13th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.
Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said the clinical study for its biologic drug Itolizumab for the possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs Controller General of India. Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing.
To improve outcomes and care delivery, personalized medicine is the ideal from the point of view of patients and clinicians alike. Digital health tools and wearable devices play a critical role in helping to make personalized health a reality. These instruments capture person-generated health data (PGHD), which is health-related data created, recorded, or gathered by individuals or by their family members and other caregivers. Personal information may be reported directly and continuously at home or on the go using a variety of digital tools, including wearable devices or phones, apps, and electronic surveys. This data is often viewed as the missing puzzle piece needed to provide a holistic, 360-degree view of the patients’ lived experience outside the clinic walls.
Swiss Parenterals receives EU GMP approval